An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice

Study acronym: IN-REALITY
StatusActive, Not Recruiting
PhaseNot specified
SponsorBayer
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later across 2 updates Jun 30, 2026 → Oct 31, 2026
See other at-risk trials from Bayer

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 12 entries Show 4 more changesShow less
    • Primary and study completion pushed from Sep 30, 2026 to Oct 31, 2026
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 3 of 7 entries
    • Study description expanded, about 10 words
  2. Primary and study completion pushed from Jun 30, 2026 to Sep 30, 2026
    • Site details revised
    v18
  3. 3 versions Re-verified since Apr 9, 2026, no change to tracked fieldsv15-v17
  4. Primary and study completion dates: Apr 30, 2026 to Jun 30, 2026
    • Start date: Sep 23, 2025 to Sep 22, 2025
    v14
  5. Site details revisedv13
Show 11 earlier versionsHide 11 earlier versions
  1. Primary and study completion dates: Jan 31, 2026 to Apr 30, 2026
    • Site details revised
    v12
  2. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Start date changed from estimate of Sep 19, 2025 to Sep 23, 2025
    v11
  3. Start date: Aug 25, 2025 to Sep 19, 2025v10
  4. Start date: Aug 1, 2025 to Aug 25, 2025v9
  5. Re-verified, no change to tracked fieldsv8
  6. Start date: Jun 2, 2025 to Aug 1, 2025
    • Primary and study completion dates: Dec 1, 2025 to Jan 31, 2026
    v7
  7. Re-verified, no change to tracked fieldsv6
  8. Start date: May 1, 2025 to Jun 2, 2025
    • Primary and study completion dates: Oct 31, 2025 to Dec 1, 2025
    v5
  9. Start date: Feb 28, 2025 to May 1, 2025
    • Primary and study completion dates: Jun 30, 2025 to Oct 31, 2025
    v4
  10. Re-verified, no change to tracked fieldsv3
  11. Start date: Jan 1, 2025 to Feb 28, 2025
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Bayer
131 trials monitored
See 11 trials at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
Type 2 Diabetes
2,236 trials monitored
See 113 trials at risk
Chronic Kidney Disease
1,423 trials monitored
See 70 trials at risk
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Trial Details
NCT Number NCT06763146
Lead Sponsor Bayer
Conditions
(from sponsor)		 Chronic Kidney Disease, Type 2 Diabetes Mellitus
Related terms Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Enrollment 1,200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov